Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Tiziana Life Sciences to Raise $3.3 Million in London IPO

Don't Miss Out —
Follow us on:

March 30 (Bloomberg) -- Tiziana Life Sciences Plc, a U.K. developer of an experimental treatment for late-stage breast cancer, is planning to raise 2 million pounds ($3.3 million) in a London initial public offering.

Tiziana aims to sell 16.7 million shares for 12 pence each and list them on AIM, the London Stock Exchange’s market for smaller companies, co-founder and executive Chairman Gabriele Cerrone said in an interview. The founders will retain about 75 percent of the company, he said.

Tiziana is founded on research at the European Cancer Stem Cell Research Institute in Cardiff, Wales. Scientists there have identified the BCL3 gene as a drug target to halt the spread of metastatic breast cancer to other parts of the body, potentially preventing the disease from becoming life-threatening. A study in mice showed that suppressing the BCL3 gene inhibited the development of metastatic tumors. Human trials may begin in 2016.

Cerrone has founded eight other biotech companies, including Trovagene Inc., Synergy Pharmaceuticals Inc. and FermaVir Pharmaceuticals, which merged with Inhibitex Inc. in 2007.

Current options for patients with metastatic breast cancer include chemotherapy, radiation therapy, hormone therapy and targeted drugs such as Roche Holding AG’s Herceptin and GlaxoSmithKline Plc’s lapatinib for those who are HER2-positive. If successful, Tiziana’s product will likely be combined with existing therapies, said Richard Clarkson, one of the scientific founders of the company.

There’s also early evidence that the BCL3 approach could be translated to other solid tumor cancers such as colorectal, prostate, and ovarian, Clarkson said.

Cairn Financial Advisers LLP and Beaufort Securities Ltd. are advising the company on the share sale.

Cerrone is also founder of Gensignia, which will also list in London by the end of the third quarter.

To contact the reporter on this story: Makiko Kitamura in London at mkitamura1@bloomberg.net

To contact the editors responsible for this story: Phil Serafino at pserafino@bloomberg.net Thomas Mulier, Kristen Hallam

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.